Related Experiment Videos
Gender impact on first trimester markers in Down syndrome screening
Severin Olesen Larsen1, Karen R Wøjdemann, Anne-Cathrine Shalmi
1Department of Clinical Biochemistry, Statens Serum Institut, Copenhagen, Denmark. sol@ssi.dk
Prenatal Diagnosis
|December 13, 2002
Summary
Fetal gender significantly impacts first-trimester prenatal screening. Female fetuses showed 16% higher free beta human chorionic gonadotropin (betahCG) levels compared to male fetuses in this study.
Area of Science:
- Prenatal diagnostics
- Maternal-fetal medicine
- Biochemical markers in pregnancy
Background:
- First-trimester screening uses serological markers and nuchal translucency.
- Accurate interpretation of these markers is crucial for assessing fetal risk.
Purpose of the Study:
- To investigate the influence of fetal gender on key first-trimester serological markers.
- To analyze the impact of fetal sex on alpha-fetoprotein (AFP), pregnancy-associated plasma protein-A (PAPP-A), and free beta human chorionic gonadotropin (betahCG) levels.
Main Methods:
- Analysis of data from 2637 singleton pregnancies with normal outcomes.
- Regression analysis of log marker values adjusted for gestational age (crown rump length) and maternal weight.
- Comparison of mean log MoM values between male and female fetuses.
Main Results:
- Fetal gender demonstrated a significant impact on free beta human chorionic gonadotropin (betahCG) levels.
- Free betahCG levels were found to be 16% higher in pregnancies with female fetuses compared to male fetuses.
- No significant gender impact was noted for AFP or PAPP-A levels.
Conclusions:
- Fetal gender is a confounding factor in first-trimester screening, particularly for free betahCG.
- Adjusting for fetal gender may improve the accuracy of prenatal screening interpretation.
- Further research is needed to understand the clinical implications of this gender-specific difference.